Overview

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.

Phase:

PHASE3

Details

Lead Sponsor:

RHEACELL GmbH & Co. KG

Collaborator:

FGK Clinical Research GmbH